Progestins in the fertility-sparing treatment and retreatment of patients with primary and recurrent endometrial cancer

Oncologist

Volumn 20, Issue 3, 2015, Pages 270-278

  Park, Jeong Yeol ^a   Nam, Joo Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Conservative; Endometrial cancer; Fertility sparing; Progestin

Indexed keywords

GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; PROGESTERONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

AGE; ARTICLE; CANCER RECURRENCE; DRUG ACTIVITY; DRUG MECHANISM; ENDOMETRIUM CANCER; FEMALE; FEMALE FERTILITY; HUMAN; HYSTERECTOMY; INTRAUTERINE CONTRACEPTIVE DEVICE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADENOCARCINOMA; ENDOMETRIAL NEOPLASMS; FERTILITY PRESERVATION; PATHOLOGY; PATIENT SELECTION; QUALITY OF LIFE; RETREATMENT; TUMOR RECURRENCE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROGESTINS; QUALITY OF LIFE; RETREATMENT;

EID: 84925387336     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0445     Document Type: Article

References (116)

1. Bray F, Loos AH, Oostindier M et al. Geographic and temporal variations in cancer of the corpus uteri: Incidence and mortality in pre- and post-menopausal women in Europe. Int J Cancer 2005; 117:123–131.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.
3. Jung KW, Won YJ, Kong HJ et al. Cancer statistics in Korea: Incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013;45:1–14.
4. Huang CY, Chen CA, Chen YL et al. Nationwide surveillance in uterine cancer: Survival analysis and the importance of birth cohort: 30-year population-based registry in Taiwan. PLoS One 2012;7:e51372.
5. Ushijima K.Current status ofgynecologic cancer in Japan. J Gynecol Oncol 2009;20:67–71.
6. Crissman JD, Azoury RS, Barnes AE et al. Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 1981;57:699–704.
7. Gallup DG, Stock RJ. Adenocarcinoma of the endometriuminwomen40yearsof ageor younger. Obstet Gynecol 1984;64:417–420.
8. Soliman PT, Oh JC, Schmeler KM et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105: 575–580.
9. Duska LR, Garrett A, Rueda BR et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol 2001;83:388–393.
10. Creasman WT, Morrow CP, Bundy BN et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(suppl):2035–2041.
11. Boronow RC, Morrow CP, Creasman WT et al. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63:825–832.
12. Park JY, Kim DY, Kim TJ et al. Hormonal therapy for women with stage IA endometrial cancer of all grades. Obstet Gynecol 2013;122:7–14.
13. Park JY, Lee SH, Seong SJ et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 2013; 129:7–11.
14. Park JY, Kim DY, Kim JH et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrialcancer(KGOG2002). EurJCancer2013; 49:868–874.
15. Shan W, Wang C, Zhang Z et al. Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia. J Gynecol Oncol 2014;25:214–220.
16. Kim MK, Seong SJ. Conservative treatment for atypical endometrial hyperplasia: What is the most effective therapeutic method? J Gynecol Oncol 2014;25:164–165.
17. Minig L, Franchi D, Boveri S et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011;22:643–649.
18. Kim MK, Seong SJ, Kim YS et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol 2013;209:358.
19. Gotlieb WH, Beiner ME, Shalmon B et al. Outcome of fertility-sparing treatment with proges-tins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718–725.
20. Bahamondes L, Ribeiro-Huguet P, de Andrade KC et al. Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand 2003;82:580–582.
21. Abu Hashim H, Zayed A, Ghayaty E et al. LNG-IUS treatment of non-atypical endometrial hyper-plasia in perimenopausal women: A randomized controlled trial. J Gynecol Oncol 2013;24:128–134.
22. Signorelli M, Caspani G, Bonazzi C et al. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: A prospective single-institution experience of 21 cases. BJOG 2009;116:114–118.
23. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434–440.
24. Wang CB, Wang CJ, Huang HJ et al. Fertility-preserving treatment in young patients with en-dometrial adenocarcinoma. Cancer 2002;94: 2192–2198.
25. Lai CH, Hsueh S, Chao AS et al. Successful pregnancy after tamoxifen and megestrol acetate therapy for endometrial carcinoma. Br J Obstet Gynaecol 1994;101:547–549.
26. Kung FT, Chen WJ, ChouHH et al. Conservative management ofearly endometrial adenocarcinoma with repeat curettage and hormone therapy under assistance of hysteroscopy and laparoscopy. Hum Reprod 1997;12:1649–1653.
27. Huang SY, Jung SM, Ng KK et al. Ovarian metastasisinanulliparouswomanwithendometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol 2005;97:652–655.
28. Burnett AF, Bahador A, Amezcua C. Anastro-zole, an aromatase inhibitor, and medroxyproges-terone acetate therapy in premenopausal obese women with endometrial cancer: A report of two cases successfully treated without hysterectomy. Gynecol Oncol 2004;94:832–834.
29. Banno K, Kisu I, Yanokura M et al. Progestin therapy for endometrial cancer: The potential of fourth-generation progestin. Int J Oncol 2012;40: 1755–1762.
30. Shimizu Y, Takeuchi T, Mita S et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod 2009;15:693–701.
31. Quick CM, May T, Horowitz NS et al. Low-grade, low-stage endometrioid endometrial adenocarci-noma: A clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion. Int J Gynecol Pathol 2012;31:337–343.
32. Ehrlich CE, Young PC, Stehman FB et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796–807.
33. Navarria I, Usel M, Rapiti E et al. Young patients with endometrial cancer: How many could be eligible for fertility-sparing treatment? Gynecol Oncol 2009;114:448–451.
34. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 2005;17:299–308.
35. Lancaster JM, Powell CB, Kauff ND et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007; 107:159–162.
36. Dijkhuizen FP, Mol BW, Brölmann HA et al.The accuracyofendometrialsamplinginthe diagnosis of patients with endometrial carcinoma and hyperpla-sia: A meta-analysis. Cancer 2000;89:1765–1772.
37. Stovall TG, Photopulos GJ, Poston WM et al. Pipelle endometrial sampling in patients with known endometrial carcinoma. Obstet Gynecol 1991;77:954–956.
38. Guido RS, Kanbour-Shakir A, Rulin MC et al. Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer. J Reprod Med 1995;40:553–555.
39. Trimble CL, Kauderer J, Zaino R et al. Concur-rentendometrial carcinomainwomen withabiopsy diagnosis of atypical endometrial hyperplasia: A Gynecologic Oncology Group study. Cancer 2006; 106:812–819.
40. Larson DM, Johnson KK, Broste SK et al. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endo-metrial cancer. Obstet Gynecol 1995;86:38–42.
41. Kempson RL, Pokorny GE. Adenocarcinoma of theendometriuminwomenagedfortyandyounger. Cancer 1968;21:650–662.
42. Shibahara H, Shigeta M, Toji H et al. Successful pregnancyinaninfertile patient with conservatively treated endometrial adenocarcinoma after transfer of embryos obtained by intracytoplasmic sperm injection. Hum Reprod 1999;14:1908–1911.
43. Symonds I. Ultrasound, hysteroscopy and endometrial biopsyin the investigation ofendome-trial cancer. Best Pract Res Clin Obstet Gynaecol 2001;15:381–391.
44. Obermair A, Geramou M, Gucer F et al. Does hysteroscopy facilitate tumor cell dissemination?: Incidence of peritoneal cytology from patients with early stage endometrial carcinoma following dilatation and curettage (D&C) versus hysteroscopy and D&C. Cancer 2000;88:139–143.
45. Selvaggi L, Cormio G, CeciO et al. Hysteroscopy does not increase the risk of microscopic extrauter-ine spread in endometrial carcinoma. Int J Gynecol Cancer 2003;13:223–227.
46. Biewenga P, de Blok S, Birnie E. Does diagnostic hysteroscopy in patients with stage I endometrial carcinoma cause positive peritoneal washings? Gynecol Oncol 2004;93:194–198.
47. Bergeron C, Nogales FF, Masseroli M et al. A multicentric European study testing the reproduc-ibility of the WHO classification of endometrial hyperplasia with a proposal of a simplified working classification for biopsy and curettage specimens. Am J Surg Pathol 1999;23:1102–1108.
48. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403-412.
49. Nofech-Mozes S, Ismiil N, Dube V et al. Interobserver agreement for endometrial cancer characteristics evaluated on biopsy material. Obstet Gynecol Int 2012;2012:414086.
50. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003;80:1315-1324.
51. Kaku T, Yoshikawa H, Tsuda H et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. Cancer Lett 2001;167:39-48.
52. Jacques SM, Qureshi F, Munkarah A et al. Interinstitutional surgical pathology review in gynecologic oncology: II. Endometrial cancer in hysterectomy specimens. Int J Gynecol Pathol 1998;17:42-45.
53. Fujiwara H, Shibahara H, Usui R et al. Unsuspected uterine carcinosarcoma (heterologous) diagnosed following conservative therapies with medroxyprogesterone acetate for presumed early-stage endometrial carcinoma. Am J Reprod Immunol 2002;47:129-131.
54. Kinkel K, KajiYYu KK et al. Radiologic staging in patients with endometrial cancer: A meta-analysis. Radiology 1999;212:711-718.
55. Varpula MJ, Klemi PJ. Staging of uterine endometrial carcinoma with ultra-low field (0.02 T) MRI: A comparative study with CT. J Comput Assist Tomogr 1993;17:641-647.
56. Hardesty LA, Sumkin JH, Hakim C et al. The ability of helical CT to preoperatively stage endometrial carcinoma. AJR Am J Roentgenol 2001;176: 603-606.
57. DelMaschio A, Vanzulli A, Sironi S et al. Estimating the depth of myometrial involvement by endometrial carcinoma: Efficacy of transvaginal sonography vs MR imaging. AJR Am J Roentgenol 1993;160:533-538.
58. Yamashita Y, Mizutani H, Torashima M et al. Assessment of myometrial invasion by endometrial carcinoma: Transvaginal sonography vs contrast-enhanced MR imaging. AJR Am J Roentgenol 1993; 161:595-599.
59. Zarbo G, Caruso G, Caruso S et al. Endometrial cancer: Preoperative evaluation of myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol Oncol 2000;21:95-97.
60. Barwick TD, Rockall AG, Barton DP et al. Imaging of endometrial adenocarcinoma. Clin Radiol 2006;61:545-555.
61. Chang MC, Chen JH, Liang JA et al. 18F-FDG PET or PET/CT for detection of metastatic lymph nodes in patients with endometrial cancer: A systematic review and meta-analysis. Eur J Radiol 2012;81: 3511-3517.
62. Park JY, Kim EN, Kim DY et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol Oncol 2008;108:486-492.
63. Evans-Metcalf ER, Brooks SE, Reale FR et al. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998;91:349-354.
64. Gitsch G, Hanzal E, Jensen D et al. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995;85:504-508.
65. Walsh C, Holschneider C, Hoang Y et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005;106: 693–699.
66. Yamanoi K, Mandai M, Suzuki A et al. Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis. Oncol Lett 2012;4:375–380.
67. Chen L, Zhao Q, Lv X. Characteristics and prognosis of coexisting adnexa malignancy with endometrial cancer:A single institution reviewof51 cases. Arch Gynecol Obstet 2011;283:1133–1137.
68. Lee TS, Jung JY, Kim JW et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol 2007;104: 52–57.
69. Williams MG, Bandera EV, Demissie K et al. Synchronous primary ovarian and endometrial cancers:Apopulation-based assessmentofsurvival. Obstet Gynecol 2009;113:783–789.
70. van Niekerk CC, Vooijs GP, Bulten J et al. Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor. Mod Pathol 2007;20: 384–388.
71. Beard CM, Hartmann LC, Keeney GL et al. Endometrial cancer in Olmsted County, MN: Trends in incidence, risk factors and survival. Ann Epidemiol 2000;10:97–105.
72. Song T, Seong SJ, Bae DS et al. Synchronous primary cancers of the endometrium and ovary in young women: A Korean Gynecologic Oncology Group Study. Gynecol Oncol 2013;131:624–628.
73. Ramirez PT, Frumovitz M, Bodurka DC et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: A literature review. Gynecol Oncol 2004;95:133–138.
74. Tangjitgamol S, Manusirivithaya S, Hanpra-sertpong J. Fertility-sparing in endometrial cancer. Gynecol Obstet Invest 2009;67:250–268.
75. Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 2010;20:1170–1187.
76. Kumar N, Koide SS, Tsong Y et al. Nestorone: A progestin with a unique pharmacological profile. Steroids 2000;65:629–636.
77. Schindler AE, Campagnoli C, Druckmann R et al. Classification and pharmacology ofprogestins. Maturitas 2003;46(suppl 1):S7–S16.
78. Baker J, Obermair A, Gebski V et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrialhyperplasia with atypia or early endometrial adenocarcinoma: A meta-analysis and systematic review of the literature. Gynecol Oncol 2012;125:263–270.
79. Nilsson CG, Haukkamaa M, Vierola H et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocri-nol (Oxf) 1982;17:529–536.
80. Montz FJ, Bristow RE, Bovicelli A et al. In-trauterine progesterone treatment of early endo-metrial cancer. Am J Obstet Gynecol 2002;186: 651–657.
81. Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17:1736–1744.
82. Chiva L, Lapuente F, González-Cortijo L et al. Sparing fertility in young patients with endometrial cancer. Gynecol Oncol 2008;111(suppl):S101–S104.
83. Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 1998;83: 111-121.
84. Reifenstein EC Jr. The treatment of advanced endometrial cancer with hydroxyprogesteronecap-roate. Gynecol Oncol 1974;2:377-414.
85. Kim MK, Seong SJ, Song T et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol 2013;130:470-473.
86. Yu D, Wong YM, Cheong Y et al. Asherman syndrome: One century later. Fertil Steril 2008;89: 759-779.
87. Taskin O, Onoglu A, Inal M et al. Long-term histopathologic and morphologic changes after thermal endometrial ablation. J Am Assoc Gynecol Laparosc 2002;9:186-190.
88. Sentilhes L, Sergent F, Roman H et al. Late complications of operative hysteroscopy: Predicting patients at riskof uterine rupture duringsubsequent pregnancy. Eur J Obstet Gynecol Reprod Biol 2005; 120:134-138.
89. Kesterson JP, Fanning J. Fertility-sparing treatment of endometrial cancer: Options, outcomesand pitfalls. J Gynecol Oncol 2012;23:120-124.
90. Chiva de Agustń L, Lapuente Sastre F, Corraliza Galan V et al. Conservative management of patients with early endometrial carcinoma: A systematic review. Clin Transl Oncol 2008;10:155-162.
91. Gadducci A, Spirito N, Baroni E et al. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: A debated therapeutic option. Gynecol Endocrinol 2009;25:683-691.
92. Gunderson CC, Fader AN, Carson KA et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: A systematic review. Gynecol Oncol 2012;125: 477-482.
93. Dorais J, Dodson M, Calvert J et al. Fertility-sparing management of endometrial adenocarcinoma. Obstet Gynecol Surv 2011;66:443-451.
94. Bovicelli A, D’Andrilli G, Giordano A et al. Conservative treatment of early endometrial cancer. J Cell Physiol 2013;228:1154-1158.
95. Rackow BW, Arici A. Endometrial cancer and fertility. CurrOpin Obstet Gynecol 2006;18:245-252.
96. Benshushan A. Endometrial adenocarcinoma in young patients: Evaluation and fertility-preserving treatment. Eur J Obstet Gynecol Reprod Biol 2004;117:132-137.
97. Kalogiannidis I, Agorastos T. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. J Obstet Gynaecol 2011;31:13-17.
98. Gallos ID, Yap J, Rajkhowa M et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: A systematic review and metaanalysis. Am J Obstet Gynecol 2012;207:266.
99. Cormio G, Martino R, Loizzi V et al. A rare case of choroidal metastasis presented after conservative management of endometrial cancer. Int J Gynecol Cancer 2006;16:2044-2048.
100. Ferrandina G, Zannoni GF, Gallotta V et al. Progression of conservatively treated endometrial carcinoma after full term pregnancy: A case report. Gynecol Oncol 2005;99:215-217.
101. Ota T, Yoshida M, Kimura M et al. Clinico-pathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005;15:657-662.
102. Ushijima K, Yahata H, Yoshikawa H et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-2803.
103. Sardi J, Anchezar Henry JP, Paniceres G et al. Primary hormonal treatment for early endometrial carcinoma. Eur J Gynaecol Oncol 1998;19:565-568.
104. Zuckerman B, Lavie O, Neuman M et al. Endoemtrial cancer stage I-grade II: Conservative treatment followed by a healthy twin pregnancy. Int J Gynecol Cancer 1998;8:172-174.
105. Imai M, Jobo T, Sato R et al. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol 2001;22:217-220.
106. Koskas M, Yazbec kC, Walker F et al. Fertility-sparing management of grade 2 and 3 endometrial adenocarcinomas. Anticancer Res 2011;31:3047-3049.
107. Brown AJ, Westin SN, Broaddus RR et al. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 2012; 119:423-426.
108. Eftekhar Z, Izadi-Mood N, Yarandi F et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: Our experiences with 21 patients. Int J Gynecol Cancer 2009;19:249-252.
109. Perri T, Korach J, Gotlieb WH et al. Prolonged conservative treatment of endometrial cancer patients: More than 1 pregnancy can be achieved. Int J Gynecol Cancer 2011;21:72-78.
110. Yu M, Yang JX, Wu M et al. Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 2009;92: 2122-2124.
111. Park JY, Seong SJ, Kim TJ et al. Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol 2013;121:136-142.
112. Sovino H, Sir-Petermann T, Devoto L. Clomi-phene citrate and ovulation induction. Reprod Biomed Online 2002;4:303-310.
113. Althuis MD, Moghissi KS, Westhoff CL et al. Uterine cancer after use of clomiphene citrate to induceovulation. Am J Epidemiol 2005;161:607-615.
114. Dor J, Lerner-Geva L, Rabinovici J et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002; 77:324–327.
115. Jensen A, Sharif H, Kjaer SK. Use of fertility drugs and riskof uterine cancer: Results from a large Danish population-based cohort study. Am J Epidemiol 2009;170:1408-1414.
116. Silva IS, Wark PA, McCormack VA et al. Ovulation-stimulation drugs and cancer risks: A long-term follow-up of a British cohort. Br J Cancer 2009;100:1824-1831.